Factor structure and external validity of the PANSS revisited.
paper
Cited
Public
Unavailable
- Authors
- Van den Oord, Edwin J C G; Rujescu, Dan; Robles, Jaime R; Giegling, Ina; Birrell, Claire; BukszΓ‘r, JΓ³zsef; Murrelle, Lenn; MΓΆller, Hans-JΓΌrgen; Middleton, Lefkos; Muglia, Pierandrea
- Year
- 2006
- Journal
- Schizophrenia research
- PMID
- 16229988
- DOI
- 10.1016/j.schres.2005.09.002
Considerable controversy exists concerning the positive and negative syndrome scale (PANSS), one of the most widely used instruments in schizophrenia research. In this article we revisited the factor structure and external validity of the PANSS in a sample of 500 participants with DSM IV diagnoses of schizophrenia. We found that a model with six latent factors provided a relatively good fit, considered adequate by two rules of thumb. Five factors corresponded closely to those typically derived in other studies: Negative, Positive, Excited/Activation, Anxious-Depressed/Dysphoric, and Disorganized/Autistic preoccupation. The sixth factor seemed to have face validity and was labeled Withdrawn. With the exception of Anxious-Depressed/Dysphoric, Cronbach's Alpha ranged from 0.70 to 0.85 suggesting an acceptable internal consistency. External validity was studied through correlations with socio-demographic variables, DSM IV (subtype) diagnoses, clinical characteristics, and drug use. The many significant correlations suggested that the six PANSS scales measure meaningful aspects of schizophrenia. Furthermore, the pattern of correlations varied, providing evidence that the scales assessed partly different aspects of the disease. Our analyses also suggested that some of the controversy about the PANSS can possibly be attributed to methodological factors where the substantial cross-loadings of some PANSS items may play an important role.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Plasma neurotransmitter-related metabolite alterations in adolescent major depressive disorder with and without psychotic features. | Luo J et al. | β | 2026 | β |
| Aripiprazole Lauroxil Every 2Β Months for the Treatment of Adults With Schizophrenia: A Post Hoc Analysis of Efficacy by Baseline Severity of Illness From Phase 3b Clinical Trial Data. | Kane JM et al. | β | 2025 | β |
| COSMIN review of the PANSS Marder factor solution and other factor models in people with schizophrenia. | Roithmeier M et al. | β | 2025 | β |
| Fear and Anxiety in Schizophrenia: A Focus on Development, Assessment, and Mechanisms. | Feola B et al. | β | 2025 | β |
| How childhood adversities shape minds and lives: An analysis across the affective-to-psychotic spectrum. | Greiner SK et al. | β | 2025 | β |
| A pragmatic randomized controlled exploratory trial of the effectiveness of Eye Movement Desensitization and Reprocessing therapy for psychotic disorder. | Marlow S et al. | β | 2024 | β |
| COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy. | Bondrescu M et al. | β | 2024 | β |
| Corpus callosum microstructural organization mediates the effects of physical neglect on social cognition in schizophrenia. | Corley E et al. | β | 2024 | β |
| Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders. | Bondrescu M et al. | β | 2024 | β |
| RETRACTED: Left hemisphere lateralization of the limbic system and frontoparietal network (FPN) correlates with positive and negative symptom improvement following cannabidiol (CBD) administration in psychosis and ultra-high risk (UHR) populations: A voxel-wise meta-analysis. | Pierce ZP et al. | β | 2024 | β |
| Uncinate fasciculus microstructural organisation and emotion recognition in schizophrenia: controlling for hit rate bias. | Stevens M et al. | β | 2024 | β |
| Use of a novel study insight analytics (SIA) methodology to improve PANSS data quality and signal detection in a global clinical trial in schizophrenia. | Opler M et al. | β | 2024 | β |
| Bilateral anterior corona radiata microstructure organisation relates to impaired social cognition in schizophrenia. | Burke T et al. | β | 2023 | β |
| The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender. | Sulejmanpasic G et al. | β | 2023 | β |
| Visual processing deficits in patients with schizophrenia spectrum and bipolar disorders and associations with psychotic symptoms, and intellectual abilities. | LΓΈchen AR et al. | β | 2023 | β |
| A review of risky decision-making in psychosis-spectrum disorders. | Purcell JR et al. | β | 2022 | β |
| Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study. | Yildiz M et al. | β | 2022 | β |
| Corpus Callosum Microstructural Tract Integrity Relates to Longer Emotion Recognition Reaction Time in People with Schizophrenia. | Burke T et al. | β | 2022 | β |
| The Correlation of PANSS Scores and P100 Latency in Patients with Schizophrenia and Migrene Hedache Using Visual Evoked Potentials (VEPS) According to Gender and Age. | Sulejmanpasic G et al. | β | 2022 | β |
| Abnormal semantic processing of threat words associated with excitement and hostility symptoms in schizophrenia. | Dar S et al. | β | 2021 | β |
| Clinical insight, cognitive insight and metacognition in psychosis: Evidence of mediation. | Lysaker PH et al. | β | 2021 | β |
| Differences in patterns of metabolic abnormality and metabolic syndrome between early-onset and adult-onset first-episode drug-naive schizophrenia patients. | Lang X et al. | β | 2021 | β |
| Hair cortisol, social support, personality traits, and clinical course: differences in schizophrenia and bipolar disorder. | Yang F et al. | β | 2021 | β |
| Intrinsic Connectivity Patterns of Task-Defined Brain Networks Allow Individual Prediction of Cognitive Symptom Dimension of Schizophrenia and Are Linked to Molecular Architecture. | Chen J et al. | β | 2021 | β |
| Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. | Lim K et al. | β | 2021 | β |
| Plasma fatty acid-binding protein 7 concentration correlates with depression/anxiety, cognition, and positive symptom in patients with schizophrenia. | Koga M et al. | β | 2021 | β |
| The association of metacognition with emotion recognition and perspective taking in a Russian sample with psychosis. | Lysaker PH et al. | β | 2021 | β |
| Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. | Maffioletti E et al. | β | 2020 | β |
| Cognitive validation of cross-diagnostic cognitive subgroups on the schizophrenia-bipolar spectrum. | Karantonis JA et al. | β | 2020 | β |
| Connectivity patterns of task-specific brain networks allow individual prediction of cognitive symptom dimension of schizophrenia and link to molecular architecture | Chen J et al. | β | 2020 | β |
| Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. | Watts JJ et al. | β | 2020 | β |
| Neurobiological Divergence of the Positive and Negative Schizophrenia Subtypes Identified on a New Factor Structure of Psychopathology Using Non-negative Factorization: An International Machine Learning Study. | Chen J et al. | β | 2020 | β |
| Polymorphisms in CRYBB2 encoding Ξ²B2-crystallin are associated with antisaccade performance and memory function. | Giegling I et al. | β | 2020 | β |
| Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. | Fountoulakis KN et al. | β | 2019 | β |
| Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses. | Anderson AE et al. | β | 2018 | β |
| Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs. | Kanchanatawan B et al. | β | 2018 | β |
| Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. | Yang Z et al. | β | 2018 | β |
| Functional connectivity during affective mentalizing in criminal offenders with psychotic disorders: Associations with clinical symptoms. | Harenski CL et al. | β | 2018 | β |
| Microstructural Findings in White Matter Associated with Cannabis and Alcohol Use in Early-Phase Psychosis: A Diffusion Tensor Imaging and Relaxometry Study. | Cookey J et al. | β | 2018 | β |
| Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia. | Hopkins SC et al. | β | 2018 | β |
| Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. | Peitl V et al. | β | 2017 | β |
| Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. | Kanchanatawan B et al. | β | 2017 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Creating Live Interactions to Mitigate Barriers (CLIMB): A Mobile Intervention to Improve Social Functioning in People With Chronic Psychotic Disorders. | Biagianti B et al. | β | 2016 | β |
| Engagement with the auditory processing system during targeted auditory cognitive training mediates changes in cognitive outcomes in individuals with schizophrenia. | Biagianti B et al. | β | 2016 | β |
| Extent and pattern of burden of care and its associated factors among Eritrean families of persons living with schizophrenia: a cross-sectional study. | Hidru TH et al. | β | 2016 | β |
| Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. | Huang M et al. | β | 2016 | β |
| The course of negative symptom in first episode psychosis and the relationship with social recovery. | Gee B et al. | β | 2016 | β |
| The Positive and Negative Syndrome Scale (PANSS): A Three-Factor Model of Psychopathology in Marginally Housed Persons with Substance Dependence and Psychiatric Illness. | Giesbrecht CJ et al. | β | 2016 | β |
| Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations. | Thokagevistk K et al. | β | 2016 | β |
| Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes. | Stepniak B et al. | β | 2015 | β |
| Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. | Di Lorenzo G et al. | β | 2015 | β |
| Baseline social amotivation predicts 1-year functioning in UHR subjects: A validation and prospective investigation. | Lam M et al. | β | 2015 | β |
| Neural correlates of out-group bias predict social impairment in patients with schizophrenia. | Blackford JU et al. | β | 2015 | β |
| Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness? | Anderson A et al. | β | 2015 | β |
| The Longitudinal Course of Gross Motor Activity in Schizophrenia - Within and between Episodes. | Walther S et al. | β | 2015 | β |
| A cross-national factor analytic comparison of three models of PANSS symptoms in schizophrenia. | Stefanovics EA et al. | β | 2014 | β |
| Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version. | Higuchi CH et al. | β | 2014 | β |
| Mild expression differences of MECP2 influencing aggressive social behavior. | Tantra M et al. | β | 2014 | β |
| Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders. | Noordraven EL et al. | β | 2014 | β |
| Multilevel ordinal factor analysis of the positive and negative syndrome scale (PANSS). | Stochl J et al. | β | 2014 | β |
| Negative symptoms, past and present: a historical perspective and moving to DSM-5. | Malaspina D et al. | β | 2014 | β |
| No association between NRG1 and ErbB4 genes and psychopathological symptoms of schizophrenia. | Tosato S et al. | β | 2014 | β |
| The nature of the relationship of psychomotor slowing with negative symptomatology in schizophrenia. | Bervoets C et al. | β | 2014 | β |
| The relationship between meteorological conditions and homicide, suicide, rage, and psychiatric hospitalization. | Talaei A et al. | β | 2014 | β |
| The UK national evaluation of the development and impact of Early Intervention Services (the National EDEN studies): study rationale, design and baseline characteristics. | Birchwood M et al. | β | 2014 | β |
| The validity and reliability of the Turkish version of the bipolar depression rating scale. | Batmaz S et al. | β | 2014 | β |
| Aberrant intrinsic brain activity and cognitive deficit in first-episode treatment-naive patients with schizophrenia. | He Z et al. | β | 2013 | β |
| A comparison of the PANSS pentagonal and Van Der Gaag 5-factor models for assessing change over time. | Jerrell JM et al. | β | 2013 | β |
| A rasch model to test the cross-cultural validity in the positive and negative syndrome scale (PANSS) across six geo-cultural groups. | Khan A et al. | β | 2013 | β |
| Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia. | Rodriguez-Jimenez R et al. | β | 2013 | β |
| Correlations of theory of mind deficits with clinical patterns and quality of life in schizophrenia. | Urbach M et al. | β | 2013 | β |
| Effect of parental age on treatment response in adolescents with schizophrenia. | Opler M et al. | β | 2013 | β |
| Emotional experience in negative symptoms of schizophrenia--no evidence for a generalized hedonic deficit. | Oorschot M et al. | β | 2013 | β |
| Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia. | Ascher-Svanum H et al. | β | 2013 | β |
| Multimodal neuroimaging of frontal white matter microstructure in early phase schizophrenia: the impact of early adolescent cannabis use. | Bernier D et al. | β | 2013 | β |
| Quantitative psychomotor dysfunction in schizophrenia: a loss of drive, impaired movement execution or both? | Docx L et al. | β | 2013 | β |
| Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. | Birchwood M et al. | β | 2013 | β |
| Testing the psychopathology of psychosis: evidence for a general psychosis dimension. | Reininghaus U et al. | β | 2013 | β |
| Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. | Liemburg E et al. | β | 2013 | β |
| Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia. | Jerrell JM et al. | β | 2013 | β |
| Validated five-factor model of positive and negative syndrome scale for schizophrenia in Chinese population. | Jiang J et al. | β | 2013 | β |
| Changes in cognitive function associated with syndrome changes on two five-factor models of the Positive and Negative Syndrome Scale. | Jerrell JM et al. | β | 2012 | β |
| Examination of anomalous self-experience: initial study of the structure of self-disorders in schizophrenia spectrum. | Raballo A et al. | β | 2012 | β |
| Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. | Wallwork RS et al. | β | 2012 | β |
| The lack of impact of quality-of-life measures in schizophrenia: a shared responsibility? | Boyer L et al. | β | 2012 | β |
| The relationships of positive and negative symptoms with neuropsychological functioning and their ability to predict verbal memory in psychotic major depression. | Che AM et al. | β | 2012 | β |
| Abnormal temporal and parietal magnetic activations during the early stages of theory of mind in schizophrenic patients. | Vistoli D et al. | β | 2011 | β |
| Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. | Clark SL et al. | β | 2011 | β |
| Association of VSNL1 with schizophrenia, frontal cortical function, and biological significance for its gene product as a modulator of cAMP levels and neuronal morphology. | Braunewell KH et al. | β | 2011 | β |
| Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. | Messinger JW et al. | β | 2011 | β |
| Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. | Citrome L et al. | β | 2011 | β |
| Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. | McClay JL et al. | β | 2011 | β |
| Neural basis of semantic priming in schizophrenia during a lexical decision task: a magneto-encephalography study. | Vistoli D et al. | β | 2011 | β |
| Patient subgroups of schizophrenia based on the Positive and Negative Syndrome Scale: composition and transition between acute and subsided disease states. | Huang GH et al. | β | 2011 | β |
| Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis. | Malcolm CP et al. | β | 2011 | β |
| Recommendations to improve the positive and negative syndrome scale (PANSS) based on item response theory. | Levine SZ et al. | β | 2011 | β |
| Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS). | Khan A et al. | β | 2011 | β |
| Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. | Montoya A et al. | β | 2011 | β |
| Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. | Saccone NL et al. | β | 2010 | β |
| Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. | Domenici E et al. | β | 2010 | β |
| Population-based linkage analysis of schizophrenia and bipolar case-control cohorts identifies a potential susceptibility locus on 19q13. | Francks C et al. | β | 2010 | β |
| A genome-wide investigation of SNPs and CNVs in schizophrenia. | Need AC et al. | β | 2009 | β |
| A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. | van den Oord EJ et al. | β | 2009 | β |
| Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity. | Nucci G et al. | β | 2009 | β |
| Objectively measured motor activity in schizophrenia challenges the validity of expert ratings. | Walther S et al. | β | 2009 | β |
| Structural differences within negative and depressive syndrome dimensions in schizophrenia, organic brain disease, and major depression: A confirmatory factor analysis of the positive and negative syndrome scale. | Eisenberg DP et al. | β | 2009 | β |
| A new rating scale for negative symptoms: the Motor-Affective-Social Scale. | TrΓ©meau F et al. | β | 2008 | β |
| Scales to assess psychosis in Parkinson's disease: Critique and recommendations. | Fernandez HH et al. | β | 2008 | β |
| Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. | Koutsouleris N et al. | β | 2008 | β |
| Altered orbitofrontal sulcogyral pattern in schizophrenia. | Nakamura M et al. | β | 2007 | β |
| Item response analysis of the Positive and Negative Syndrome Scale. | Santor DA et al. | β | 2007 | β |
| LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia. | Francks C et al. | β | 2007 | β |
| Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. | Opler MG et al. | β | 2007 | β |
| Symptom rating scales and outcome in schizophrenia. | Mortimer AM | β | 2007 | β |